Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed th...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2012-09-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756285612453972 |
| _version_ | 1818405154451357696 |
|---|---|
| author | Verena Isabell Leussink Leila Husseini Clemens Warnke Erasmia Broussalis Hans-Peter Hartung Bernd C. Kieseier |
| author_facet | Verena Isabell Leussink Leila Husseini Clemens Warnke Erasmia Broussalis Hans-Peter Hartung Bernd C. Kieseier |
| author_sort | Verena Isabell Leussink |
| collection | DOAJ |
| description | A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS. |
| first_indexed | 2024-12-14T08:51:32Z |
| format | Article |
| id | doaj.art-e88a0144aee44cb7aa4a3e740d21e756 |
| institution | Directory Open Access Journal |
| issn | 1756-2856 1756-2864 |
| language | English |
| last_indexed | 2024-12-14T08:51:32Z |
| publishDate | 2012-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-e88a0144aee44cb7aa4a3e740d21e7562022-12-21T23:09:02ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28561756-28642012-09-01510.1177/1756285612453972Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticityVerena Isabell LeussinkLeila HusseiniClemens WarnkeErasmia BroussalisHans-Peter HartungBernd C. KieseierA large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impact on their quality of life. Anecdotal evidence suggests a beneficial effect of cannabis on spasticity as well as pain. Recently, randomized, double-blind, placebo-controlled studies have confirmed the clinical efficacy of cannabinoids for the treatment of spasticity in patients with MS. Based on these data, nabiximols (Sativex), a 1:1 mix of Δ-9-tetrahydrocannabinol and cannabidiol extracted from cloned Cannabis sativa chemovars, received approval for treating MS-related spasticity in various countries around the globe. In this article we review the current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS.https://doi.org/10.1177/1756285612453972 |
| spellingShingle | Verena Isabell Leussink Leila Husseini Clemens Warnke Erasmia Broussalis Hans-Peter Hartung Bernd C. Kieseier Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity Therapeutic Advances in Neurological Disorders |
| title | Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity |
| title_full | Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity |
| title_fullStr | Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity |
| title_full_unstemmed | Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity |
| title_short | Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity |
| title_sort | symptomatic therapy in multiple sclerosis the role of cannabinoids in treating spasticity |
| url | https://doi.org/10.1177/1756285612453972 |
| work_keys_str_mv | AT verenaisabellleussink symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity AT leilahusseini symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity AT clemenswarnke symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity AT erasmiabroussalis symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity AT hanspeterhartung symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity AT berndckieseier symptomatictherapyinmultiplesclerosistheroleofcannabinoidsintreatingspasticity |